MX362383B - Moduladores de acido oxabiciclo[2.2.2] gpr120. - Google Patents

Moduladores de acido oxabiciclo[2.2.2] gpr120.

Info

Publication number
MX362383B
MX362383B MX2015011913A MX2015011913A MX362383B MX 362383 B MX362383 B MX 362383B MX 2015011913 A MX2015011913 A MX 2015011913A MX 2015011913 A MX2015011913 A MX 2015011913A MX 362383 B MX362383 B MX 362383B
Authority
MX
Mexico
Prior art keywords
oxabicicle
gpr120
acid modulators
modulators
compounds
Prior art date
Application number
MX2015011913A
Other languages
English (en)
Other versions
MX2015011913A (es
Inventor
T W Cheng Peter
C Wu Shung
Zhang Hao
Tao Shiwei
Chen Sean
A Negash Lidet
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2015011913A publication Critical patent/MX2015011913A/es
Publication of MX362383B publication Critical patent/MX362383B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención proporciona compuestos de la Fórmula (I): (I) o un estereoisómero, o una sal farmacéuticamente aceptable del mismo, en donde todas las variables son como se define aquí. Estos compuestos son moduladores del receptor acoplado a la proteína G GPR12O que pueden ser utilizados como medicamentos.
MX2015011913A 2013-03-14 2014-03-13 Moduladores de acido oxabiciclo[2.2.2] gpr120. MX362383B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782339P 2013-03-14 2013-03-14
US14/205,421 US8962660B2 (en) 2013-03-14 2014-03-12 Oxabicyclo [2.2.2] acid GPR120 modulators
PCT/US2014/025287 WO2014151247A1 (en) 2013-03-14 2014-03-13 Oxabicyclo [2.2.2] acid gpr120 modulators

Publications (2)

Publication Number Publication Date
MX2015011913A MX2015011913A (es) 2015-12-09
MX362383B true MX362383B (es) 2019-01-15

Family

ID=51529985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011913A MX362383B (es) 2013-03-14 2014-03-13 Moduladores de acido oxabiciclo[2.2.2] gpr120.

Country Status (13)

Country Link
US (1) US8962660B2 (es)
EP (1) EP2970327B1 (es)
JP (1) JP2016512556A (es)
KR (1) KR20150128860A (es)
CN (1) CN105189516B (es)
AU (1) AU2014235172B2 (es)
BR (1) BR112015021596A2 (es)
CA (1) CA2905448A1 (es)
EA (1) EA201591805A1 (es)
IL (1) IL241323B (es)
MX (1) MX362383B (es)
SG (1) SG11201506799RA (es)
WO (1) WO2014151247A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2852590B1 (en) * 2012-04-27 2017-02-01 Novartis AG Cyclic bridgehead ether dgat1 inhibitors
PT2920165T (pt) * 2012-11-16 2016-12-20 Bristol Myers Squibb Co Moduladores de diidropirazol gpr40
CA2905428A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Bicyclo [2.2.1] acid gpr120 modulators
MX366820B (es) 2013-03-14 2019-07-25 Bristol Myers Squibb Co Moduladores de gpr120 del acido biciclo[2.2.2].
EP2860177A3 (en) * 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
US20170327457A1 (en) 2014-09-09 2017-11-16 Bristol-Myers Squibb Company Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators
EP3191454B1 (en) 2014-09-09 2018-10-24 Bristol-Myers Squibb Company Cyclopropanecarboxylic acid gpr120 modulators
US10023519B2 (en) 2014-09-09 2018-07-17 Bristol-Myers Squibb Company Cyclobutane containing carboxylic acid GPR120 modulators
KR20170031400A (ko) 2015-09-11 2017-03-21 주식회사 만도 전자식 브레이크 시스템
WO2017161145A1 (en) 2016-03-18 2017-09-21 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase and/or epx
CN110225752B (zh) 2016-09-12 2023-05-05 整体健康 用作gpr120调节器的单环化合物
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
EP3765446A1 (en) 2018-03-15 2021-01-20 AXXAM S.p.A. Substituted pyrazoles ffa4/gpr120 receptor agonists
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN113366000A (zh) 2018-09-18 2021-09-07 百时美施贵宝公司 作为lpa拮抗剂的氧杂双环酸
US20220204547A1 (en) * 2019-05-09 2022-06-30 Fermenta Biotech Limited Novel method for synthesizing 25-oh cholesterol/calcifediol from phytosterol
CN111233889B (zh) * 2020-03-02 2021-09-14 北方民族大学 一种噻吩并[3,4-b]-1,4-二噁英-2-甲醇衍生物的制备方法
CN115490586A (zh) * 2021-06-17 2022-12-20 北京中医药大学 一种微波辅助的高效神经酸合成方法
CN113912619B (zh) * 2021-11-26 2022-12-06 沈阳药科大学 五味子中提取分离的倍半萜化合物及其方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
EP2305684A1 (en) 1999-11-12 2011-04-06 Biogen Idec MA Inc. Poycyloalkylpurines as adenosine receptor antagonists
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
MY151167A (en) * 2005-04-15 2014-04-30 Eisai R&D Man Co Ltd Benzimidazole compound
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
CL2008003407A1 (es) 2007-11-16 2010-01-11 Boehringer Ingelheim Int Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
CN101932562B (zh) * 2007-12-20 2013-06-12 阿斯利康(瑞典)有限公司 作为dgat1抑制剂190的氨基甲酰基化合物
EP2364088B1 (en) 2008-10-30 2014-04-16 Biogen Idec MA Inc. Bicyclic aryl sphingosine 1-phosphate analogs
AU2010303670A1 (en) 2009-10-06 2012-03-29 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
EP2687507B1 (en) 2011-03-14 2016-03-09 Taisho Pharmaceutical Co., Ltd. Nitrogen-containing condensed heterocyclic compound
EP2852590B1 (en) * 2012-04-27 2017-02-01 Novartis AG Cyclic bridgehead ether dgat1 inhibitors
US9120798B2 (en) 2012-08-01 2015-09-01 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor
US9714231B2 (en) 2012-11-16 2017-07-25 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators
MX2015005858A (es) 2012-11-16 2015-09-24 Bristol Myers Squibb Co Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.

Also Published As

Publication number Publication date
KR20150128860A (ko) 2015-11-18
CN105189516A (zh) 2015-12-23
IL241323A0 (en) 2015-11-30
BR112015021596A2 (pt) 2017-07-18
JP2016512556A (ja) 2016-04-28
US20140275173A1 (en) 2014-09-18
CN105189516B (zh) 2017-08-15
US8962660B2 (en) 2015-02-24
WO2014151247A1 (en) 2014-09-25
EP2970327A1 (en) 2016-01-20
AU2014235172B2 (en) 2018-04-26
IL241323B (en) 2018-10-31
CA2905448A1 (en) 2014-09-25
EA201591805A1 (ru) 2016-01-29
EP2970327B1 (en) 2017-05-03
SG11201506799RA (en) 2015-09-29
MX2015011913A (es) 2015-12-09
AU2014235172A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
MX2020006315A (es) Acidos carbamoil ciclohexilicos ligados a n triazol como antagonistas de acido lisofosfatidico (lpa).
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
UY35818A (es) Composiciones y métodos para modular los receptores x farnesoides
UY35143A (es) Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
MX388170B (es) Polimorfos de selinexor
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201590381A1 (ru) Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
EA201691141A1 (ru) Соединения против ccr6
MX394645B (es) Compuestos heteroaromáticos como inhibidores de vanina.
MX2015011375A (es) Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1].
SV2017005381A (es) Compuestos de imidazopiridazina
MX2016013801A (es) Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes.
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm
BR112015029598A2 (pt) inibidores de di-hidropiridinona mgat2
BR112018070363A2 (pt) derivados de tetraidroisoquinolina
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX2016010529A (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).

Legal Events

Date Code Title Description
FG Grant or registration